AVEO PHARMACEUTICALS INC. overview

BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO’s Special Meeting of Stockholders (the “Special Meeting”) “FOR” the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. (“LG Chem”), a subsidiary of LG Chem and AVEO (the “merger...

– Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Announced entering a definitive agreement under which LG Chem will acquire AVEO for $15.00 per share in an all-cash transaction with an implied equity value of $566 million on a fully diluted basis – BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines...

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of AVEO Pharmaceuticals, Inc. - AVEO PR Newswire NEW YORK, Oct. 24, 2022 NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating...

SHAREHOLDER ALERT: Weiss Law Investigates AVEO Pharmaceuticals, Inc. PR Newswire NEW YORK, Oct. 21, 2022 NEW YORK , Oct. 21, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ: AVEO), in connection with the proposed acquisition of the Company by LG Chem, Ltd. Under the terms of the merger agreement, the Company's shareholders will receive $15.00...

Shareholder Alert: Ademi LLP investigates whether AVEO Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with LG Chem PR Newswire MILWAUKEE, Oct. 18, 2022 MILWAUKEE , Oct. 18, 2022 /PRNewswire/ -- Ademi LLP is investigating AVEO (NASDAQ: AVEO) for possible breaches of fiduciary duty and other violations of law in its transaction with LG Chem. Click here to learn how to join the action https://www.ademilaw.com/case/aveo-pharmaceuticals-inc or call Guri Ademi toll-free at...

Thinking about buying stock in RA Medical, Aveo Pharmaceuticals, FuboTV, Canoo, or 89bio? PR Newswire NEW YORK, Oct. 18, 2022 NEW YORK , Oct. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RMED, AVEO, FUBO, GOEV, and ETNB. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. RMED:...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) to LG Chem, Ltd. for $15.00 per share is fair to AVEO shareholders. Halper Sadeh encourages AVEO shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com . The investigation concerns whether AVEO and its board of directors violated the...

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced today that, as disclosed on uspto.gov, the United States Patent and Trademark Office (“USPTO”) has allowed U.S. Patent Application No. 17/720,619, titled “Use of Tivozanib to Treat Subjects with Refractory Cancer” (the “Application”). AVEO expects to...